Urofollitropin

Urofollitropin is a form of follicle-stimulating hormone prepared by extracting and purifying the hormone from the urine of postmenopausal women, whose bodies produce large amounts of gonadotropins. Purification removes most other urinary proteins to yield a product containing FSH with little luteinising hormone activity, and highly purified versions are refined further. It belongs to the gonadotropin class of fertility drugs and differs from menotropins, or human menopausal gonadotropin, which contains both FSH and LH activity, and from recombinant FSH, which is made in cell culture rather than collected from urine ^[1].

In clinical use, urofollitropin drives the growth and maturation of ovarian follicles. It is used to induce ovulation in women who do not ovulate, particularly those with polycystic ovary syndrome who have not responded to first-line tablets, and it is a component of controlled ovarian stimulation for assisted reproductive techniques such as in vitro fertilisation, typically followed by human chorionic gonadotropin to trigger final egg maturation ^[1]. To limit complications from too many follicles developing, ovulation-induction regimens use gradual, low-dose schedules ^[1].

Comparative trials have found urinary and recombinant FSH to be broadly equivalent. Randomised studies in women undergoing assisted reproduction reported similar numbers of eggs retrieved and similar pregnancy and live-birth rates with highly purified urinary FSH and recombinant FSH ^[2][3]. Recombinant products are often more convenient, while urinary preparations can be less expensive, so both retain a role ^[1].

Urofollitropin is given by subcutaneous or intramuscular injection, with the dose individualised to the woman's response and monitored by ultrasound and hormone measurements.

The main risks are those of ovarian stimulation, chiefly ovarian hyperstimulation syndrome and an increased chance of multiple pregnancy, and local injection-site reactions, abdominal or pelvic pain and bloating are common ^[1]. It is a prescription-only medicine and sits among the fertility gonadotropins used worldwide; certain batches of the brand Bravelle were recalled for being under-potent in the mid-2010s. As a drug that stimulates ovulation, it is used only under specialist supervision.

Urofollitropin is prescription only and used under specialist supervision. Its most important risk is ovarian hyperstimulation syndrome, where the ovaries overrespond, swell, and leak fluid, which in severe cases causes abdominal pain, bloating, blood clots, and breathing trouble. It also raises the chance of multiple pregnancy, such as twins or more. Other effects include injection site reactions, headache, mood changes, breast tenderness, and pelvic discomfort. Careful monitoring with ultrasound and blood estradiol guides dosing to reduce these risks. It is avoided when there is uncontrolled thyroid or adrenal disease, an ovarian cyst not from polycystic ovaries, undiagnosed vaginal bleeding, or certain hormone-sensitive tumors. Treatment is stopped or adjusted if the response looks excessive.

Urofollitropin belongs to the family of urine-derived gonadotropins whose story began in the mid-twentieth century, when researchers learned that the urine of postmenopausal women is rich in the pituitary hormones that stimulate the ovaries. Early preparations combined follicle-stimulating hormone with luteinizing hormone, but as fertility medicine matured, manufacturers sought purer products containing predominantly FSH so that ovarian stimulation could be controlled more precisely.

Urofollitropin was developed as such a purified, and later highly purified, follicle-stimulating hormone extracted and refined from pooled postmenopausal urine. It has been marketed under brand names including Metrodin, Bravelle, and Fostimon and became a mainstay for ovulation induction and for the controlled ovarian stimulation used in in vitro fertilization. Even after recombinant FSH became available, urofollitropin remained clinically relevant, and comparative trials have shown it produces follicular responses comparable to the recombinant hormone.

Urofollitropin holds a well-established and trusted place in reproductive medicine, with a decades-long record of helping induce ovulation and support assisted reproduction. Its reputation rests on reliability; because it delivers follicle-stimulating hormone that acts on exactly the same ovarian receptors as the body's own hormone, its effects are predictable and its efficacy in stimulating follicle growth is well documented.

Clinical studies have found it comparable to recombinant FSH in the follicular responses it produces, making it a cost-conscious yet effective option in many fertility programs. As with all gonadotropins, its power carries inherent risks, chiefly ovarian hyperstimulation syndrome and an increased chance of multiple pregnancy, which is why treatment is carefully monitored by specialists. Within that supervised setting, urofollitropin is regarded as a dependable and valued tool for building families.